Fennec Pharmaceuticals (FENC) Issues Earnings Results

Share on StockTwits

Fennec Pharmaceuticals (NASDAQ:FENC) announced its earnings results on Wednesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01), MarketWatch Earnings reports.

Shares of FENC stock opened at $6.01 on Thursday. Fennec Pharmaceuticals has a 12 month low of $5.33 and a 12 month high of $14.99. The company has a market cap of $136.29 million, a PE ratio of -12.79 and a beta of -0.23.

A number of equities research analysts have issued reports on FENC shares. HC Wainwright set a $18.00 target price on Fennec Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 21st. Zacks Investment Research lowered Fennec Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 28th. Finally, Wedbush reiterated an “outperform” rating and set a $16.00 price target on shares of Fennec Pharmaceuticals in a report on Thursday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $15.00.

An institutional investor recently raised its position in Fennec Pharmaceuticals stock. Geode Capital Management LLC raised its holdings in shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) by 16.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,489 shares of the company’s stock after buying an additional 5,441 shares during the quarter. Geode Capital Management LLC owned about 0.20% of Fennec Pharmaceuticals worth $251,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 48.99% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Fennec Pharmaceuticals (FENC) Issues Earnings Results” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4220307/fennec-pharmaceuticals-fenc-issues-earnings-results.html.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Featured Article: Understanding Specialty Certificates of Deposit

Earnings History for Fennec Pharmaceuticals (NASDAQ:FENC)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Allakos  Downgraded by Zacks Investment Research to “Hold”
Allakos Downgraded by Zacks Investment Research to “Hold”
ABIOMED  Upgraded to Hold by BidaskClub
ABIOMED Upgraded to Hold by BidaskClub
Consumer Edge Begins Coverage on Lamb Weston
Consumer Edge Begins Coverage on Lamb Weston
Nike  Stock Rating Reaffirmed by Credit Suisse Group
Nike Stock Rating Reaffirmed by Credit Suisse Group
Vermilion Energy  Cut to Hold at Zacks Investment Research
Vermilion Energy Cut to Hold at Zacks Investment Research
Smartsheet  Upgraded at Zacks Investment Research
Smartsheet Upgraded at Zacks Investment Research


© 2006-2019 Ticker Report